Par Health Appoints Dr. William Larkins as EVP and Chief Scientific Officer to Lead Sterile Injectables Par Health has named Dr. William Larkins as EVP and Chief Scientific Officer. His deep expertise in sterile injectables aims to drive company growth and innovation.

Par Health Appoints Dr. William Larkins as EVP and Chief Scientific Officer to Lead Sterile Injectables #United_States #St._Louis #Par_Health #sterile_injectables #Dr._Larkins

Par Health Emerges as Independent Leader in Generic Pharmaceuticals and Sterile Injectables Par Health has successfully spun off from Mallinckrodt, establishing itself as a top U.S. player in generic drugs and sterile injectables, poised for growth.

Par Health Emerges as Independent Leader in Generic Pharmaceuticals and Sterile Injectables #United_States #St._Louis #pharmaceuticals #Generic_Drugs #Par_Health

Mallinckrodt's New Journey: Introducing Keenova Therapeutics Post Spin-Off of Par Health Mallinckrodt completes the spin-off of Par Health and unveils Keenova Therapeutics, focusing on innovative therapies for unmet patient needs.

Mallinckrodt's New Journey: Introducing Keenova Therapeutics Post Spin-Off of Par Health #Ireland #Dublin #Mallinckrodt #Par_Health #Keenova

Mallinckrodt and Endo Craft Merger to Form a Leading Global Therapeutics Powerhouse Discover the groundbreaking merger between Mallinckrodt and Endo, which aims to create a diverse global leader in therapeutics focused on addressing significant medical needs.

Mallinckrodt and Endo Craft Merger to Form a Leading Global Therapeutics Powerhouse #United_States #Dublin #Mallinckrodt #Endo #Par_Health

Mallinckrodt and Endo Reveal Leadership Team for Future Combined Company The merger between Mallinckrodt and Endo is set to foster a strong leadership team focused on innovative pharmaceutical advancements and patient care.

Mallinckrodt and Endo Reveal Leadership Team for Future Combined Company #United_States #Mallinckrodt #Endo #Par_Health #Dublin,_Malvern